Jason A. Leverone's most recent trade in OnKure Therapeutics Inc. - Ordinary Shares - Class A was a trade of 303 Class A Common Stock done at an average price of $2.4 . Disclosure was reported to the exchange on June 23, 2025.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
OnKure Therapeutics Inc. -... | Jason A. Leverone | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 2.38 per share. | 23 Jun 2025 | 303 | 12,906 | - | 2.4 | 722 | Class A Common Stock |
OnKure Therapeutics Inc. -... | Jason A. Leverone | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 2.67 per share. | 04 Apr 2025 | 1,844 | 13,209 | - | 2.7 | 4,925 | Class A Common Stock |
OnKure Therapeutics Inc. -... | Jason A. Leverone | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 3.33 per share. | 04 Apr 2025 | 1,278 | 15,053 | - | 3.3 | 4,253 | Class A Common Stock |
OnKure Therapeutics Inc. -... | Jason A. Leverone | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jan 2025 | 65,000 | 65,000 | - | - | Employee Stock Option (right to buy) | |
OnKure Therapeutics Inc. -... | Jason A. Leverone | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Oct 2024 | 130,611 | 130,611 | - | - | Employee Stock Option (right to buy) | |
OnKure Therapeutics Inc. -... | Jason A. Leverone | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Oct 2024 | 16,331 | 16,331 | - | - | Class A Common Stock | |
OnKure Therapeutics Inc. -... | Jason A. Leverone | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Oct 2024 | 5,781 | 5,781 | - | - | Employee Stock Option (right to buy) | |
OnKure Therapeutics Inc. -... | Jason A. Leverone | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Oct 2024 | 5,322 | 5,322 | - | - | Employee Stock Option (right to buy) | |
Viridian Therapeutics Inc | Jason A. Leverone | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2021 | 311,785 | 311,785 | - | - | Employee Stock Option (right to buy) |